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ABSTRACT
Background: Previously, we showed that reintroduction of the same (first-line) chemotherapy at pro-
gression could only partially make up for the loss in efficacy as compared to continuously delivered
first-line chemotherapy. Here, we report the probability of starting second-line study chemotherapy in
the Stop&Go trial, and the progression-free survival (PFS) and overall survival (OS) of patients who
received both the first- and second-line treatment in an intermittent versus continuous schedule.
Methods: First-line chemotherapy comprised paclitaxel plus bevacizumab, second-line capecitabine or
non-pegylated liposomal doxorubicin, given per treatment line as two times four cycles (intermittent)
or as eight consecutive cycles (continuous).
Results: Of the 420 patients who started first-line treatment within the Stop&Go trial (210:210), a total of
270 patients continued on second-line study treatment (64% of all), which consisted of capecitabine in
201 patients and of non-pegylated liposomal doxorubicin in 69 patients, evenly distributed between the
treatment arms. Median PFS was 3.7 versus 5.0months (HR 1.07; 95% CI: 0.82–1.38) and median OS 10.9
versus 12.4months (HR 1.27; 95% CI: 0.98–1.66) for intermittent versus continuous second-line chemother-
apy. Second-line PFS was positively influenced by prior hormonal therapy for metastatic disease and longer
first-line PFS duration, while triple-negative tumor status had a negative influence. Patients with a shorter
time to progression (TTP) in first-line (10months) had a higher probability of starting second-line treat-
ment if they received intermittent compared to continuous chemotherapy (OR 1.97; 95% CI: 1.02–3.80).
Conclusion: We recommend continuous scheduling of both the first- and second-line chemotherapy
for advanced breast cancer.
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Background
Although several improvements have been made in the
treatment of early breast cancer, advanced breast cancer
remains largely incurable with a median survival of
2–3 years [1,2]. Treatment of patients with advanced breast
cancer focuses both on improving length and quality of life,
but the optimal duration of a particular line of chemotherapy
is still not clarified [3]. This results in a high variety of treat-
ment strategies in daily clinical practice, with some using a
predefined number of cycles and others continuing treat-
ment till progression of disease (PD) or unacceptable toxicity.
Considering the fact that the likelihood of response to each
subsequent line of treatment decreases, optimization of
especially the initial treatment lines may be important.
A previous meta-analysis of 11 randomized trials on shorter
(4–6 cycles) versus longer (8–12 cycles) chemotherapy dura-
tions reported inferior PFS results with shorter durations of
treatment [4]. However, most of the trials included in this
pooled analysis comprised outdated treatment agents, with
only three trials investigating taxane-containing treatments,
showing inconclusive results [5–7]. As taxanes are suggested
for first-line chemotherapy by current guidelines [3], the ques-
tion remained if these recommendations were also applicable
for these modern agents, with expected higher efficacy in the
initial treatment cycles. Therefore, the Stop&Go study
intended to make a comparison of an interrupted versus a
continued chemotherapy schedule with agents that were fre-
quently used in current clinical practice.
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The Stop&Go trial is a phase III trial, investigating the efficacy
and tolerability of intermittent versus continuous scheduling of
the first two chemotherapy lines [8]. For first-line chemotherapy
[8], we found that reintroduction of the same therapy at progres-
sion (intermittent schedule) could only partially make up for the
loss in efficacy as compared to continuously delivered chemother-
apy. In the current exploratory analysis, we focus on the results of
second-line treatment scheduling. We hypothesized that the most
efficient treatment approach in first-line (intermittent or continu-
ous) would lead to a differential patient selection in second-line
and to an increased effectiveness in second-line and overall, when
using the same approach in second-line.
Methods
Study design and participants
The randomized, open-label phase III Stop&Go trial was con-
ducted at hospitals affiliated to the Dutch Breast Cancer
Research Group (BOOG). Patients with HER2-negative incur-
able locally advanced or metastatic breast cancer who were
candidates for first-line chemotherapy and who fulfilled the
eligibility criteria were randomized to intermittent or con-
tinuous chemotherapy [8]. Participants were allocated in a
1:1 ratio by minimization, using the computer program ALEA
(https://www.tenalea.com/nkiavl/alea/Default.aspx).
Stratification factors included institute, hormone receptor sta-
tus and site of disease (visceral versus non-visceral). No pla-
cebo treatments were used. After allocation, participants
were to receive the same treatment strategy (intermittent or
continuous) both in first- and in second-line (no cross-over
and no repeated randomization).
The study was conducted in agreement with the
Declaration of Helsinki (version 1 May 1996) and local regula-
tions (ethics committee Eindhoven, the Netherlands). All par-
ticipants provided written informed consent. The study
protocol is registered at the EU Clinical Trials Register, num-
ber 2010-021519-18 (https://www.clinicaltrialsregister.eu/ctr-
search/search?query=2010-021519-18).
In the intermittent treatment arm, four cycles of chemother-
apy were given followed by another four cycles of the same
treatment, if a PD-event occurred 3months after the initial
cycles. If PD occurred <3months or after a second PD after re-
introduction, second-line treatment had to be started if the
patient was still fit enough. In the continuous treatment arm, a
maximum of eight cycles of chemotherapy were given succes-
sively in both first- and second-line (Figure 1), without re-intro-
duction at PD. In the current analysis, we determined the
effect of chemotherapy scheduling in the patients who were
able to receive both first- and second-line study treatment.
Treatment and assessments
First-line treatment consisted of paclitaxel 90mg/m2 intra-
venously on days 1, 8 and 15, combined with bevacizumab
10mg/kg intravenously on days 1 and 15, repeated every
28 days. Bevacizumab maintenance was continued at 15mg/
kg once every 21 days until the occurrence of PD or
unacceptable toxicity. For extensive information, see previous
publication [8]. Second-line treatment consisted of either
capecitabine at 1000mg/m2 orally BID for 2weeks, followed
by 1week off, or of non-pegylated liposomal doxorubicin
intravenously at 60mg/m2 once every 3weeks, chosen at the
discretion of the physician and depending on prior use of
anthracyclines in the adjuvant setting. Receiving endocrine-
or other systemic anti-tumor treatments – during the study
period was considered a major protocol violation, leading to
censoring within the PFS analyses.
Toxicity-related dose adjustment or treatment delays were
to be performed according to dose-modification guidelines
described in the study protocol (see Online Supplement).
Disease response assessment was based on local clinical
evaluation according to the RECIST criteria version 1.1 [9].
During the follow-up period, date of progression after the
end of study treatment, and start date of new anti-tumor
treatment was registered every three months until death or
study withdrawal.
Outcomes
Here, we report on secondary endpoints from the Stop&Go
study, with the main endpoint being PFS of second-line treat-
ment, calculated from the start of second-line study treatment
until the date of final progression as defined by the investiga-
tor, or death, whichever occurred first. Additionally, the com-
bined PFS of both first- and second-line treatment was
assessed, from randomization date to date of progression after
two study-line treatments, or date of progression on first-line
treatment if not started with second-line, or death, whichever
occurred first. Within the PFS analyses, patients who started
non-protocol anti-tumor treatment before PD were censored
at the date the non-protocol anti-tumor therapy was started
or at the date of last follow-up if non-progressive. OS was cal-
culated from the start of second-line study treatment as well
as from randomization. Other endpoints included predictive
factors for PFS in second-line and the probability of starting
second-line treatment. For the probability of starting second-
line treatment, patients who died during first-line treatment
were excluded. Predictive parameters included the time to
progression (TTP) in first-line treatment, defined as the time
from randomization until date of final progression defined by
the investigator. Toxicity of second-line treatment was graded
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI CTCAE) version
4.0. All AE’s grade 3 were recorded.
Statistical analyses
Sample size calculations were done based on the primary
endpoint of the Stop&Go study, first-line PFS. In order to
demonstrate non-inferiority of the intermittent arm com-
pared to the continuous arm for this endpoint with 80%
power at a 0.025 significance level, a total number of 420
patients were required for randomization to first-line treat-
ment [8]. All efficacy analyses, comparing the intermittent
with the continuous treatment arm, were performed
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according to the intention-to-treat principle. The safety ana-
lysis included all patients who received at least one dosage
of second-line study medication. PFS and OS endpoints
measured from randomization were performed on all
patients, and separately for those who started second-line
treatment. In this paper, we only report results for the
patients who received both the first- and second-line study
treatment. Results for all randomized patients are displayed
in the online supplement, and include PFS and OS endpoints
of the combined first- and second-line treatment (Online
Figure 2).
The Kaplan–Meier (KM) method was used to assess PFS
and OS, calculated from start of second-line study treatment
and from the date of randomization. Survival curves were
compared between study arms by log-rank tests. To account
for possible unbalanced compliance in the study arms with
respect to second-line treatment, a propensity score (PS)
model was estimated, and stabilized inverse probability
weights (SIPW) were calculated. Curves weighted by SIPWs
were also displayed and differences between treatment
groups were assessed. The (weighted) Cox proportional-haz-
ards model was used to estimate hazard ratios (HRs) of the
intermittent arm versus the continuous arm and their corre-
sponding 95% confidence intervals (CIs). The Cox model was
stratified by hormonal receptor status and site of disease,
and adjusted for other patient and clinical characteristics in
the case of multivariable analyses. The proportional hazards
assumption was assessed by including time-by-covariate
interaction terms in the model and scaled Schoenfeld resid-
uals plots over time. In case the hazard ratio changed over
time, Cox models were fitted for different time periods
where the assumption of proportionality might hold. No mul-
tiple imputation of missing values in clinical characteristics
was performed for multivariable analyses, as the percentage
missing was 5% or less. Relevant multivariable analyses are
displayed in the full paper. The remaining results, including
weighted analyses, are displayed in the Online Supplement
(Online Figures 2 and 3).
To model the probability of starting second-line study
treatment, a mixed-effects logistic regression was performed
among eligible patients (i.e., those alive after the end of first-
line treatment), adjusting for several patient and clinical
characteristics.
All analyses were performed using SAS (Cary, NC, USA,
version V9.4) and R (Auckland, New Zealand, version 3.5).
Results
A total of 420 participants were randomized to first-line
chemotherapy between December 2011 and March 2016
from 43 hospitals. At the time of database lock for the cur-
rent analyses (1 November 2018), median duration of fol-
low-up was 51.2months (95% CI: 48–61.3). Updated OS
analyses had an additional follow-up of 20.7months com-
pared to previously published results (previous data cutoff
3 April 2017).
Patient characteristics and received treatments
Of the 420 patients who started first-line treatment within
the Stop&Go trial (210:210), a total of 270 patients contin-
ued on second-line study treatment (64% of all), which con-
sisted of capecitabine in 201 patients and of non-pegylated
liposomal doxorubicin in 69 patients, evenly distributed
between the treatment arms (Online Figure 1). The key
characteristics at randomization were well-balanced
between treatment arms for the patients who started
second-line study treatment, and these were in line with
the baseline characteristics of the total study population
(Table 1).
Main reasons for final second-line treatment discontinu-
ation in the safety population were disease progression (55%
in both arms), major protocol violations (e.g., receiving more
than the prescribed amount of cycles; 24% versus 0%) and
toxicity (11% versus 10%), for the intermittent and the con-
tinuous arms, respectively (Online Table 2).
Figure 1. Flowchart of study design. R: randomization; P: paclitaxel; B: bevacizumab; NPLD: non-pegylated liposomal doxorubicin; PD: progressive disease; PD1-1:
first disease progression during first-line intermittent treatment; PD1-2: final disease progression during first-line intermittent treatment; PD2-1: first disease pro-
gression during second-line intermittent treatment; PD2-2: final disease progression during second-line intermittent treatment.
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PFS in second-line and combined PFS of first- and
second-line
Median PFS on second-line study treatment (n¼ 270) was
3.7months (95% CI: 2.8–4.7) for the intermittent treatment
arm versus 5.0months (95% CI: 4.4–5.9) for the continuous
treatment arm, with a HR of 1.07 (95% CI: 0.82–1.38) in a
Cox model stratified by hormonal receptor status and site of
disease (Figure 2(A)). However, the assumption of proportion-
ality of hazards was not met, so a time-by-arm interaction
term was introduced. The HR was found to decrease with
time. Period-specific HRs indicated that until 7months after
the start of second-line treatment, the risk of progression
was higher in the intermittent arm (HR 1.39; 95% CI:
1.01–1.92, adjusted for hormonal receptor status, site of dis-
ease and other patient and clinical characteristics available in
255 patients). Considering the small population of patients
left at risk at 7months, caution is required in comparing the
treatment arms beyond this point.
For the 270 patients starting second line of treatment,
the combined median PFS of first- and second-line treat-
ment was 14.6months versus 16.4months for intermittent
versus continuous chemotherapy scheduling, with a HR of
1.12 (95% CI: 0.86–1.45) (Figure 2(C)). However, the same
phenomenon was seen as for the PFS of second-line alone:
non-proportional hazards were found for study treatment.
At 12months after randomization, the PFS curve reached a
small plateau for the intermittent arm. Up until this time,
hazards for combined PFS were significantly higher with
intermittent treatment (HR 1.85; 95% CI: 1.14–3.00
adjusted for hormonal receptor status, site of disease and
other patient and clinical characteristics available in
255 patients).
Survival in second-line and combined first- and
second-line
Median OS calculated from the start of second-line study
treatment was 10.9months (95% CI: 8.2–13.4) versus
12.4months (95% CI: 10.4–15.1) for intermittent and continu-
ous treatment, respectively with a HR of 1.27 (95% CI:
0.98–1.66), in a Cox model stratified by hormonal receptor
status and site of metastasis (Figure 2(B)).
Median OS calculated from randomization was 21.0 for
intermittent versus 23.2months for continuous treatment
with a HR of 1.27 (95% CI: 0.98–1.66) for the patients who
started second-line study treatment (n¼ 270) (Figure 2(D)).
Table 1. Baseline characteristics measured at randomization for subgroups based on actually received treatment in intermittent and continuous arm (ITT popula-
tion, N¼ 420).
Intermittent arm Continuous arm
Characteristics measured at
randomization
All randomized
(N¼ 210)
Started 2nd-line study
treatment
(N¼ 131)
All randomized
(N¼ 210)
Started 2nd-line study
treatment
(N¼ 139)
Median age in years (range) 60 (36–76) 59 (38–76) 61 (28–77) 61 (28–77)
Median BMI (IQR) 25 (23–28) 25 (24–28) 26 (23–29) 26 (23–29)
ECOG PSa
0–1 197 (94%) 126 (96%) 195 (93%) 134 (96%)
2 12 (6%) 5 (4%) 15 (7%) 5 (4%)
Stage at initial diagnosisb
Stage I–III 185 (88%) 118 (90%) 187 (89%) 120 (86%)
Stage IV 16 (8%) 9 (7%) 18 (9%) 15 (11%)
Hormonal receptor statusc
ERþ and/or PgRþ 166 (79%) 104 (79%) 171 (81%) 116 (83%)
ER PgR 36 (17%) 21 (16%) 34 (16%) 19 (14%)
Median DFI (months)
between initial diagnosis
and metastatic
diagnose (IQR)
56 (25–89) 59 (30–90) 44 (21–87) 47 (23–87)
Site of metastatic disease
Visceral 20 (10%) 12 (9%) 19 (9%) 14 (10%)
Non-visceral 31 (15%) 22 (17%) 26 (12%) 21 (15%)
Combination visceral and
non-visceral
159 (76%) 97 (74%) 165 (79%) 104 (75%)
Prior (neo)adjuvant therapy
(Neo)adjuvant
chemotherapy
131 (62%) 87 (66%) 122 (58%) 82 (59%)
Adjuvant
hormonal therapy
118 (56%) 83 (63%) 110 (52%) 78 (56%)
Hormonal therapy for
M1 disease
1 line 100 (48%) 70 (53%) 93 (44%) 60 (43%)
2 lines 56 (27%) 37 (28%) 65 (31%) 41 (29%)
3 lines 31 (15%) 21 (16%) 38 (18%) 29 (21%)
There were no significant differences between treatment arms in any of the variables listed in the table above as tested by Chi-square, Ranksum and Fisher’s
exact tests.
Abbreviations: ITT: intention-to-treat; BMI: body mass index; IQR: interquartile range; ECOG PS: Eastern Cooperative Oncology Group Performance Status; ER:
estrogen receptor; PgR: progesteron receptor; DFI: disease free interval; M1: metastatic.
aMissing ECOG PS: n¼ 1 versus n¼ 0 for patients intermittent versus continuous arm.
bMissing stage at initial diagnosis: n¼ 9 versus n¼ 5 for intermittent versus continuous arm.
cMissing hormonal receptor status: n¼ 8 versus n¼ 5 for intermittent versus continuous arm.
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Factors associated with second-line PFS duration
In the exploratory multivariable Cox-regression model, receiv-
ing prior hormonal therapy for metastatic disease (HR 0.68
[95% CI: 0.50–0.91]), first-line PFS duration of >10months
versus 10months (HR 0.73 [95% CI: 0.55–0.97]), and increas-
ing age (HR 0.99 [95% CI: 0.97–1.00]), were linked to a better
second-line PFS. Conversely, patients with triple-negative
tumors had a higher risk of progression in second-line as
compared to those with hormone receptor positive/HER2-
tumors (HR 1.6; 95% CI: 1.05–2.44) (Table 2).
Factors associated with the probability of starting
second-line study treatment
The crude odds ratio (OR) for the intermittent compared to
the continuous arm with respect to starting second-line
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OS in second-line
Number at risk (censored)
(0) (0) (1) (3) (8) (12) (14) (16) (17) (17)
(0) (1) (4) (5) (8) (11) (13) (13) (15) (15)
0.0
0.2
0.4
0.6
0.8
1.0
0 6 12 18 24 30 36 42 48 54 60
Months from randomization
PF
S 
Pr
ob
ab
ilit
y
Continuous
Intermittent
139 134 104 51 20 6 2 2 1
131 122 75 43 22 13 6 5 3 2 1
Continuous
Intermittent
Median PFS  − Continuous arm: 16.4 (95%CI: 15.1 − 18.1)
Median PFS  − Intermittent arm: 14.6 (95%CI: 13.6 − 16.8)
ITT, events/n (128/139 − 118/131)
HR= 1.12 (95%CI: 0.86 − 1.45)
Combined PFS
Number at risk (censored)
(0) (0) (5) (10) (10) (11) (11) (11) (11) (0) (0)
(0) (0) (4) (8) (8) (9) (10) (11) (13) (13) (13)
0.0
0.2
0.4
0.6
0.8
1.0
0 6 12 18 24 30 36 42 48 54 60
Months from randomization
O
S 
Pr
ob
ab
ilit
y
Continuous
Intermittent
139 137 122 90 65 50 29 14 9 3 3
131 126 97 72 56 37 18 15 9 9 6
Continuous
Intermittent
Median OS  − Continuous arm: 23.2 (95%CI: 20.9 − 28.3)
Median OS  − Intermittent arm: 21.0 (95%CI: 17.2 − 24.4)
ITT, events/n (128/139 − 118/131)
HR= 1.27 (95%CI: 0.98 − 1.66)
Combined OS
Number at risk (censored)
(0) (0) (0) (0) (0) (1) (6) (11) (12) (17) (17)
(0) (0) (0) (0) (0) (0) (6) (7) (10) (10) (11)
(A) (B)
(C) (D)
Figure 2. Kaplan–Meier estimates for the subgroup of patients in the intermittent and continuous arms that started second-line study treatment in the ITT popula-
tion (n¼ 270) of: (A) progression-free survival (PFS) calculated from the start of second-line study treatment, (B) overall survival (OS) calculated from the start of
second-line study treatment, (C) combined PFS of first- and second-line study treatment, (D) OS measured from randomization. Hazard ratios (HRs) of the intermit-
tent arm versus the continuous arm and their corresponding 95% confidence intervals (CIs) were estimated using Cox proportional-hazards models, stratified by
hormone receptor status and site of disease (visceral versus non-visceral).
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study treatment was 0.90 (95% CI: 0.59–1.37). The odds of
starting second-line treatment were lower for patients with
baseline ECOG performance status 2 compared to 0–1 (OR
0.24; 95% CI: 0.09–0.63) (Table 3).
The probability of starting second-line treatment in the
different treatment arms was linked to the TTP in first-line.
Within the continuous arm, the probabilities of starting
second-line study treatment were 0.80 and 0.61 for patients
with a first-line TTP of >10months and 10months, respect-
ively. For the intermittent treatment, these probabilities were
0.68 and 0.75. To further evaluate this association, we first
looked at the treatment arms separately. For the continuous
arm, the odds of starting second-line chemotherapy in
patients with TTP >10months were significantly higher com-
pared to the odds for patients with a TTP of 10months
(adjusted OR 2.73; 95% CI: 1.36–5.46). In contrast, no evi-
dence for such interaction was found for the intermittent
treatment arm (OR 0.70; 95% CI: 0.34–1.43). Secondly, we
compared the odds of starting second-line study treatment
between treatment arms for patients with a specific TTP dur-
ation in first-line. Patients with a TTP of 10months had a
higher probability of starting second-line treatment if they
received intermittent treatment compared to continuous
treatment (OR 1.97; 95% CI: 1.02–3.80). For a TTP of
>10months, there was an indication of the opposite (OR
0.50; 95% CI: 0.24–1.06). See Table 3 for all parameters.
Toxicity of second-line treatment
Generally, the number AEs of grade 3 was lower in the
intermittent arm compared to the continuous arms. Key AEs
of grade 3 were neutropenia (5% versus 9%), palmar–plan-
tar erythro-dysesthesia syndrome (5% versus 8%), fatigue
(5% versus 8%), pain (5% versus 7%), diarrhea (2% versus
6%), dyspnea (5% versus 1%) and hypertension (13% versus
14%) for intermittent versus continuous treatment, respect-
ively (Table 4). There were two treatment-related deaths dur-
ing second-line treatment, one due to left ventricular
dysfunction and one due to hepatic failure, both in the con-
tinuous treatment-arm.
Discussion
The Stop&Go study was designed to assess the impact of
chemotherapy scheduling in first- and second-line chemo-
therapy in patients with HER2-negative advanced breast can-
cer. Previously, we reported that continuous chemotherapy
during first-line treatment might be the preferred strategy,
because of the observed trend in improved PFS and OS as
compared to intermittently delivered first-line chemotherapy
[8]. Now, we addressed the question whether maintaining
the same scheduling during second-line would further
improve outcome. Indeed, we found that continuous sched-
uling of both first- and second-line treatment showed an
improved OS by approximately two months (21.0 versus
23.2months, at a HR of 1.27 [95% CI: 0.98–1.66]). Although
there was an absence of statistical significance, results
showed a clear favorable trend for continuous treatment.
Although the observed efficacy of second-line study treat-
ment (median PFS 3.7 versus 5.0months, median OS 10.9
versus 12.4months) seemed relatively poor, results were
comparable to other studies. A review on phase II and III
studies on single-agent second-line chemotherapy for
advanced breast cancer noted median OS of 8–13months for
the majority of trials [10]. In comparison, trials reporting
second-line PFS within this review were scarce, and medians
varied from 2.5 to 9.8months depending on the investigated
single-agent [10]. Observational studies on multiple lines of
chemotherapy for advanced breast cancer reported median
second-line PFS or TTP between 2.5 and 11.7months
[11–21]. However, comparison of these outcomes between
trials is limited due to the large variety in (amount of) previ-
ous treatments, selection of patients, type of chemotherapy
and whether or not concurrent treatments were given.
To our knowledge, this is the first randomized controlled
trial that evaluated the efficacy of intermittently delivered
chemotherapy over several treatment lines. Although other
studies comparing different durations of first-line chemother-
apy found significant benefits in PFS with prolonged chemo-
therapy, effects on OS were less consistent [5,6,22–32]. From
this current study, we learned that the same phenomenon
occurred in first- and second-line study treatment; a relatively
rapid progression of disease in the period after cessation of
Table 2. Associationsa with second-line progression-free survival.
HR 95% CI p Value
Baseline characteristics
Treatment arm: intermittent versus continuous 1.15 0.87 1.53 .31
Age at randomization (years) (per additional year) 0.99 0.97–1.00 .05
ECOG PS 2 versus 0–1 0.87 0.39–1.92 .72
TN versus ERþ and/or PgRþ tumor 1.60 1.05–2.44 .03
DFI 12 months between initial diagnosis and M1 disease versus DFI >12 months 1.35 0.88–2.07 .17
Stage IV at initial diagnosis versus stage I–III 0.85 0.49–1.47 .56
Prior HT for M1 disease versus no prior HT 0.68 0.50–0.91 .01
Only non-visceral metastasis versus visceral localizations 0.87 0.58–1.30 .50
First-line treatment characteristics
First-line TTP of > 10 months versus  10 months 0.73 0.55–0.97 0.03
Abbreviations: ITT: intention-to-treat; HR: hazard ratio; 95%CI: 95% confidence interval; ECOG PS: Eastern Cooperative Oncology Group
Performance Status; HT: hormonal therapy; M1: metastatic disease; TN: triple negative: ER: estrogen receptor; PgR: progesteron receptor;
DFI: disease free interval; TTP: time to progression.
Italic values considered statistically significant. For n¼ 15 patients one or more baseline characteristics were missing.
aMultivariable Cox-regression model.
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chemotherapy within the intermittent arm compared to a
more stable course of disease within the continuous treat-
ment arm. Additionally, the exploratory multivariable Cox-
regression analysis indicated that the duration of PFS in first-
line was of significant influence on second-line PFS (Table 2).
To implement a continuous chemotherapy schedule in
clinical practice, the challenge is to use agents that provide
disease control, are well tolerated and can be continued for
a prolonged period without interruptions. Several studies
have investigated the use of low-dose metronomic chemo-
therapy schedules, indicating the ideal agents should prefer-
able be oral, have limited cumulative toxicity and low costs
[33]. Possible candidates for the treatment of advanced
breast cancer from phase I and II trials include oral cyclo-
phosphamide and methotrexate, capecitabine and oral vinor-
elbine.[33] Additionally, the effects of metronomic
chemotherapy include immune-mediated as well as endo-
crine, anti-angiogenic and stroma-targeted mechanisms, with
several studies in advanced breast cancer suggesting a pos-
sible synergistic effect of combining metronomic chemother-
apy with endocrine, immune- and/or targeted therapies
[34–41]. Future research should thus focus on continuous
administration of well-tolerated chemotherapy agents, as a
background for other therapies. Additionally, the
Table 3. Probabilitiesa of starting second-line study treatment (ITT population excluding deaths during first-line treatment, N¼ 376).
Baseline characteristics OR 95% CI p Value
Age at randomization: >65 years versus 65 years 0.81 0.49–1.36 .43
BMI: >25 versus 25 1.08 0.67–1.76 .75
ECOG PS 2 versus 0-1 0.24 0.09–0.63 .00
TN versus ERþ and/or PgRþ tumor 0.73 0.36–1.48 .38
DFI  12 months between initial diagnosis and M1 disease versus DFI > 12 months 0.56 0.28–1.10 .09
Stage IV at initial diagnosis versus stage I-III 1.35 0.49–3.69 .56
Prior HT for M1 disease versus no prior HT 1.21 0.72–2.05 .47
Only non-visceral metastasis versus visceral localizations 2.16 0.94–4.97 .07
Abbreviations: ITT: intention to treat; OR: odds ratio; 95% CI: 95% confidence interval; BMI: body mass index; ECOG PS: Eastern Cooperative
Oncology Group Performance Status; ER: estrogen receptor; PgR: progesterone receptor; DFI: disease free interval; M1: metastatic.
Italic values are considered statistically significant.
aMixed-effects logistic regression model adjusted for time to final progression (grouped versus >10months) in first-line treatment, and for
baseline characteristics.
Table 4. Adverse events Grade 3 or higher with an incidence of at least 2% in any study arm occurring during second-line, irrespective of relation to study
treatment (maximum grade) (safety population, n¼ 270)c.
Capecitabine or non-pegylated liposomal doxorubicin
Adverse event
Intermittent (N¼ 131) Continuous (N¼ 139)
All (%) Gr. 3 (%) Gr. 4 (%) Gr. 5 (%) All (%) Gr. 3 (%) Gr. 4 (%) Gr. 5 (%)
Blood and lymphatic system disorder
Anemia 4 (3) 4 (3) – – 6 (4) 5 (4) 1 (1) –
Leucopenia 4 (3) 4 (3) – – 2 (1) 1 (1) 1 (1) –
Neutropenia 7 (5) 5 (4) 2 (2) – 12 (9) 10 (7) 2 (1) –
Febrile neutropenia 3 (2) 3 (2) – – 1 (1) – 1 (1) –
Gastrointestinal disorders
Diarrhea 3 (2) 3 (2) – – 9 (6) 9 (6) – –
Mucositis oral 3 (2) 3 (2) – – 3 (2) 3 (2) – –
Nausea 4 (3) 4 (3) – – 5 (4) 5 (4) – –
Vomiting 4 (3) 4 (3) – – 4 (3) 4 (3) – –
General disorders and administration site conditions
Edema – – – – 3 (2) 3 (2) – –
Fatiguea 6 (5) 6 (5) – – 11 (8) 10 (7) 1 (1) –
Painb 7 (5) 7 (5) – – 10 (7) 10 (7) – –
Infections and infestations
Urinary tract or bladder infection – – – – 4 (3) 4 (3) – –
Lung infection 2 (2) 2 (2) – – 3 (2) 3 (2) – –
Nervous system disorders
Peripheral sensory neuropathy 4 (3) 4 (3) – – 2 (1) 2 (1) – –
Respiratory, thoracic and mediastinal disorders
Dyspnea 7 (5) 5 (4) 2 (2) – 2 (1) 2 (1) – –
Skin and subcutaneous tissue disorders
Palmar-plantar erythro-dysesthesia syndrome 7 (5) 7 (5) – – 11 (8) 11 (8) – –
Vascular disorders
Hypertension 17 (13) 17 (13) – – 20 (14) 20 (14) – –
Thromboembolic event 1 (1) 1 (1) – – 5 (4) 4 (3) 1 (1) –
Reported adverse events (AE’s) were graded using the National Cancer Institute Common Terminology Criteria for Adverse events version 4.0. The maximum
grade per patient was reported here. There were two cases of grade 5 toxicity both in the continuous treatment arm (n¼ 1 left ventricular dysfunction, n¼ 1
hepatic failure).
aFatigue also included AEs labeled malaise or performance status declined.
bPain included AEs labeled pain, back pain, abdominal pain, pelvic pain, thoracic pain, Bone pain, pain in extremity, headache, non-cardiac chest pain, pleuritic
pain and hepatic pain. Cardiac chest pain was not included.
cAdditional AEs of grade 3 or higher of special interest occurred in the following incidences, taking into account the maximum grade per patient: heart failure/
left ventricular systolic dysfunction/decreased ejection fraction n¼ 1 versus n¼ 3, myocardial infarction n¼ 0 versus n¼ 1, small intestinal perforation n¼ 1 ver-
sus n¼ 0, DPD-deficiency n¼ 1 versus n¼ 0, for the intermittent versus the continuous arm, respectively.
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implementation of continuous chemotherapy requires us to
rethink the optimal sequence of available agents. Possibly,
the more tolerable agents should be exploited first before
moving onto the more toxic agents that can only be given
for a limited amount of time.
Our current study indicated that when evaluating the
treatment lines separately, efficacy decreased (PFS in first-line
7.4 versus 9.7months; PFS in second-line 3.7 versus
5.0months for intermittent versus continuous treatment,
respectively). However, prospectively selecting the right
population of patients that could benefit from additional
treatment lines remains challenging in clinical practice.
Literature on multiple lines of chemotherapy for advanced
breast cancer proposes that the profile for suitable patients
is determined by the benefits from previous lines and the
performance status during the disease course [42]. Real-
world studies indicate that response rates [11,13,43–50] and
TTP or treatment failure [11,17–21,43–48,50,51] decline
with subsequent chemotherapy lines. Additionally, response
to and/or longer TTP or PFS of previous chemotherapy
significantly influenced time to progression or PFS on
next-line chemotherapy within multivariate analyses
[12,17,18,45,47,49–52]. In our current study, a TTP of
>10months in first-line was associated with better PFS in
second-line study treatment (Table 2). Furthermore, observa-
tional studies found similar results for OS with medians
decreasing with each supplementary chemotherapy line
[46–48,51]. Within the multivariate analyses of these studies,
response to previous treatments [18,47,48,52–54], perform-
ance status [13,19,20,54,55] and time to progression or PFS
[13,17,55] were of significant influence on OS.
A note of caution is due, since the lack of significant dif-
ferences in second-line PFS might be caused by the fact that
24% of patients in the intermittent treatment arm received
more than the allocated number of subsequent chemother-
apy cycles (major protocol violation). If these patients would
have been excluded from current analysis (a per protocol
instead of intent-to-treat analysis), differences between the
treatment arms could have been greater in disadvantage of
intermittent scheduling. Additionally, more patients were
censored due to start of non-protocol treatment (e.g., hor-
monal therapy) in the intermittent arm (n¼ 24 versus
n¼ 16). Hypothetically these protocol violations might be
due to uncertainty about the outcome caused by the chemo-
therapy-holiday, a relevant factor to take into account as
endocrine consolidation treatment is a common practice.
Another limitation includes the inability to soundly compare
the subgroups of patients that received capecitabine as
second-line study treatment (n¼ 201) with those who
receives non-pegylated liposomal doxorubicin (n¼ 69), and
the populations of patients in second-line with hormone-
receptor positive (n¼ 220) disease with those who had tri-
ple-negative disease (n¼ 40) due to the imbalanced num-
bers. In the Stop&Go study protocol, the prolonged
treatment arm consisted of eight treatment cycles. As the
toxicity of especially capecitabine is generally mild, we now
would recommend to continue therapy until progression of
disease if well-tolerated. But, based on the results of our
study we cannot make that recommendation as we did not
formally test the benefit of more than eight treatment cycles.
In conclusion, the Stop&Go study found no efficacy bene-
fits from an intermittent chemotherapy schedule across two
treatment lines. The superior period-specific progression-free
survival and the advantageous overall survival results of the
continuous schedule prompt our advice to schedule both
the first- and second-line chemotherapy for patients with
HER2-negative advanced breast cancer without interruptions.
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